Search

Your search keyword '"Sabin CA"' showing total 563 results

Search Constraints

Start Over You searched for: Author "Sabin CA" Remove constraint Author: "Sabin CA"
563 results on '"Sabin CA"'

Search Results

1. How do we measure unmet need within sexual and reproductive health? A systematic review.

2. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

5. Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV

6. sj-pdf-2-rsh-10.1177_17579139221118778 – Supplemental material for How do we measure unmet need within sexual and reproductive health? A systematic review

7. sj-pdf-1-rsh-10.1177_17579139221118778 – Supplemental material for How do we measure unmet need within sexual and reproductive health? A systematic review

8. sj-pdf-3-rsh-10.1177_17579139221118778 – Supplemental material for How do we measure unmet need within sexual and reproductive health? A systematic review

9. Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK

10. Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz

11. A systematic review of risk of HIV transmission through biting or spitting: implications for policy

12. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

13. Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK

15. Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers

16. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

17. Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data

18. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study

20. Respiratory symptoms and chronic bronchitis in people with and without HIV infection.

21. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.

22. Grey and white matter abnormalities in treated HIV-disease and their relationship to cognitive function

23. Monitoring of older HIV‐1‐positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative.

24. Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation.

27. Assessing health-related quality-of-life in individuals with haemophilia

28. HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK

29. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

30. Level of agreement between frequently used cardiovascular risk calculators in people living with HIV.

31. HIV coinfection among persons diagnosed with hepatitis B in England in 2008–2014.

32. Combination antiretroviral therapy and the risk of myocardial infarction

33. The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations

34. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure

35. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

36. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

37. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates

38. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

39. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

41. Response to combination antiretroviral therapy: Variation by age

42. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

43. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

44. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

45. Response to combination antiretroviral therapy (cART): variation by age

46. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

48. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study

49. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study

Catalog

Books, media, physical & digital resources